• Develops an integrated cell-based liquid biopsy platform for early cancer detection based on the identification of a rare cell type, known as tumor-derived circulating endothelial cells (tCEC), which can pinpoint early stages of cancer
  • Claims its technology is capable of detecting a single tCEC...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

Singaporean biotech firm Lucence continues to advance its liquid biopsy technology for early cancer diagnostics

News Commentary | March 26, 2021

In partnership with Waseda University, Lucence plans to develop a high‑speed liquid biopsy platform for early cancer detection. The technology will use laser‑based imaging to capture high‑resolution images of circulating tumor cells from blood samples. Lucence developed a single liquid biopsy test ... Not part of subscription

23andMe expands portfolio of approved cancer screenings with latest FDA approval

News Commentary | January 13, 2022

The U.S. FDA has given 23andMe approval to expand its genetic health risk report by screening for a G84E mutation in the HOXB13 gene. This mutation has been linked to an increase in prostate cancer. A recent study showed that males with a G84E gene mutation were 66% more likely to have prostate ... To read more, click here.


Company Profile | May 09, 2022

ENose develops a point‑of‑care electronic nose sensor for breath diagnostics; the company has built diagnostic models for diseases including lung cancer, breast cancer, colon cancer, prostate cancer, lung embolism, and others but is still validating with no products commercially available Its ... Not part of subscription